Double-Blind Placebo

DRUG7 trials

Conditions

Autoimmune DiseasesCOVID-19Collagen DiseasesIdiopathic HypersomniaIrritable Bowel Syndrome With DiarrheaLung FibrosisModerate to Severe Ulcerative ColitisRheumatoid Arthritis

Phase 1

A Trial of NT-I7 in COVID-19 (SPESELPIS)

TerminatedNCT04501796

NeoImmuneTechCOVID-19

Start: 2020-11-27End: 2023-02-23Updated: 2023-07-14

Phase 2

A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis

CompletedNCT04274257

Tokyo UniversityAutoimmune Diseases, Collagen Diseases, Lung Fibrosis +2

Start: 2017-12-04End: 2019-11-05Updated: 2020-02-18

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

CompletedNCT04700449

Connect Biopharm LLCModerate to Severe Ulcerative Colitis

Start: 2019-02-27End: 2022-11-10Updated: 2024-05-06

Phase 3

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

CompletedNCT00048932

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2002-12-31End: 2009-10-31Updated: 2011-11-24

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

CompletedNCT00870467

AbbottRheumatoid Arthritis

Start: 2009-03-31End: 2011-08-31Updated: 2012-08-07

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

CompletedNCT01543178

Bausch Health Americas, Inc.Irritable Bowel Syndrome With Diarrhea

Start: 2012-02-29End: 2014-06-30Updated: 2017-12-12

A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

CompletedNCT05156047

Harmony Biosciences Management, Inc.Idiopathic Hypersomnia

Start: 2022-05-25End: 2023-09-08Updated: 2024-09-19

SLEEP2025-05-01

0868 Long-Term Safety and Effectiveness of Pitolisant Use in Adult Patients with Idiopathic Hypersomnia (IH)

SLEEP2025-05-01

0867 Effect of Pitolisant on Symptoms of Idiopathic Hypersomnia During an Open-Label Period in a Phase 3 Clinical Trial

SLEEP2025-05-01

Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.

2023-03-1413 citations

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.

2022-06-2840 citations

Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial

Lara D. Veeken2022-02-0131 citations

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.

2021-05-26168 citations

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome

Gut Microbes2018-04-3081 citations

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Arthritis Research & Therapy2018-01-0128 citations

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial

Therapeutic Advances in Gastroenterology2017-09-0129 citations

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

2017-06-0635 citations

Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

2016-08-13195 citations

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases2016-06-24107 citations

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial

Lara D. Veeken2014-01-1727 citations

Double-Blind Placebo

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers